Literature DB >> 25329538

Ameloblastoma: demographic data and treatment outcomes from Melbourne, Australia.

T Singh1, D Wiesenfeld, J Clement, A Chandu, A Nastri.   

Abstract

BACKGROUND: There is a lack of published data on the demographics and treatment outcomes of ameloblastomas treated in Australia. Our objective was to collect this data and compare the findings to other international studies.
METHODS: A retrospective study of 42 patients with ameloblastoma was conducted at The Royal Melbourne Hospital, Australia. Data on the demographic features, management techniques (ablative and reconstructive), and outcomes were collected and analysed.
RESULTS: The majority of tumours were solid/multicystic (81%) and occurred most commonly in the mandible (80.5%). Unicystic ameloblastomas affected a younger age group, with Type 3 being the most common subtype. Overall, the recurrence rate for solid/multicystic ameloblastomas was 14.7%; however, radical surgery was found to have a significantly lower recurrence rate when compared to conservative management (p=0.015), with a mean of 51 months follow-up. Results indicated that vascularized free-flaps had fewer postoperative complications than non-vascularized bone grafts; however, the differences did not reach statistical significance.
CONCLUSIONS: This is the largest clinicopathological study regarding ameloblastoma management from Australia, and our results support the current literature in recommending radical surgery for the treatment of solid/multicystic and Type 3 unicystic tumours.
© 2015 Australian Dental Association.

Entities:  

Keywords:  Ameloblastoma; outcomes; reconstruction; recurrence; surgery

Mesh:

Year:  2015        PMID: 25329538     DOI: 10.1111/adj.12244

Source DB:  PubMed          Journal:  Aust Dent J        ISSN: 0045-0421            Impact factor:   2.291


  5 in total

1.  Is conservative surgery a better choice for the solid/multicystic ameloblastoma than radical surgery regarding recurrence? A systematic review.

Authors:  Yuri Slusarenko da Silva; Natalia Aguiar Tartaroti; Daniel Isaac Sendyk; Maria Cristina Zindel Deboni; Maria da Graça Naclério-Homem
Journal:  Oral Maxillofac Surg       Date:  2018-09-06

2.  The Epidemiology, treatment, and complication of ameloblastoma in East-Indonesia: 6 years retrospective study.

Authors:  M Ruslin; F-N Hendra; A Vojdani; D Hardjosantoso; M Gazali; A Tajrin; J Wolff; T Forouzanfar
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2018-01-01

3.  A geographical analysis of ethnic distribution of jaw ameloblastoma in Nigerians.

Authors:  Akinyele Olumuyiwa Adisa; Tolulope Osayomi; Olajumoke Ajibola Effiom; Bamidele Kolude; Ahmed Oluwatoyin Lawal; Olujide Oladele Soyele; Olufemi Ggenga Omitola; Adetokunbo Babajide Olawuyi; Robinson Obos Okiti; Thelma Ezeh Saiki; Benjamin Fomete; Adebayo Aremu Ibikunle; Chukwubuzor Udokwu Okwuosa; Mofoluwaso Abimbola Olajide; Adeola Mofoluwake Ladeji; Kehinde Adebiyi; Mubarak Emmanuel; Hammed Sikiru Lawal; Emeke Uwadia; Babatunde Oludare Fakuade; Yusuf Abdullahi; Constantinus Politis; Jimoh Olumide Agbaje
Journal:  Afr Health Sci       Date:  2019-03       Impact factor: 0.927

4.  Recurrent Ameloblastoma: Clinical Manifestation and Disease-Free Survival Rate.

Authors:  Andrii Hresko; Roman Palyvoda; Olha Burtyn; Yurii Chepurnyi; Andrii Kopchak; Marco Helder; Tymour Forouzanfar
Journal:  J Oncol       Date:  2022-08-09       Impact factor: 4.501

5.  Recurrence Rates of Intraosseous Ameloblastoma Cases With Conservative or Aggressive Treatment: A Systematic Review and Meta-Analysis.

Authors:  Xue Qiao; Junxiu Shi; Jiayi Liu; Jinwen Liu; Yan Guo; Ming Zhong
Journal:  Front Oncol       Date:  2021-05-19       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.